^
Association details:
| Biomarker: | MGMT promoter methylation |
|---|---|
| Cancer: | Glioblastoma |
| Drug: | Stivarga (regorafenib) (Multi-tyrosine kinase inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Clinical activity of regorafenib in elderly patients with recurrent glioblastoma
Published date:
01/10/2023
Excerpt:
Ours was a bi-centric retrospective study analyzing the role of regorafenib in recurrent glioblastoma patients >60 years....Data were than stratified for MGMT status and for age...mOS in MGMT methylated patient was statistically significant superior to that of the unmethylated group, 7.7 months (5,29-6,01) vs. 5.6 months (5,29-6,01), P 0.048 (Fig. 4.).
DOI:
10.3892/mco.2023.2605
